Sosa Regina, Garcia Pablo, Cipriano Ever O, Hernández Agualuz, Hernández Elmer E, Chavez Paola I, Manchinelli Angélica, Morales Oscar A, Flores Lourdes E, Romero Hair J, Raquec Yulany, Sapón Byron F, Soch Kevin E, Anand Shuchi, Sánchez-Polo Vicente
Department of Nephrology, Guatemalan Institute of Social Security, Guatemala City, Guatemala.
Stanford University School of Medicine, Palo Alto, California, USA.
Kidney Int Rep. 2021 Apr;6(4):1110-1117. doi: 10.1016/j.ekir.2021.01.028. Epub 2021 Jan 29.
Coronavirus disease 2019 (COVID-19) is public health concern across the world. Data on the epidemiology among patients on hemodialysis in Latin America and low- and middle-income countries are limited.
Using electronic medical records from the second largest dialysis network in Guatemala, we performed a retrospective analysis of all adult patients on hemodialysis with the diagnosis of COVID-19 to estimate incidence of infection and to describe the demographics, comorbidities, and outcomes. We stratified incidence rate by region. We reviewed data from May 1 to July 31, 2020, with outcome data ascertained up to August 28, 2020.
Of 3201 patients undergoing hemodialysis, 325 patients were diagnosed with COVID-19 (incidence rate 102/1000 patients on hemodialysis, compared with 3/1000 in the general population). Incidence was higher in the Central region (207/1000) and lowest in the Southeast region (33/1000), and unlike in the general population, the incidence was lower in Guatemala City. The mean age of patients diagnosed with COVID-19 was 51.1 years (standard deviation [SD] 14.8 years), and 84 (25.8%) were female. The median length of hospital stay was 12 days (interquartile range [IQR] 10-16 days). Two hundred twenty-nine (69.8%) of the patients recovered, 90 patients died (27.7%), and 6 (1.8%) patients were still in the hospital at the time of last follow-up.
The incidence of diagnosed COVID-19 in Guatemalan patients on hemodialysis was much higher than reported in the general population, with outcomes similar to those described in high-income countries. Rural regions had higher incidence rates than the major metropolitan area.
2019冠状病毒病(COVID-19)是全球关注的公共卫生问题。拉丁美洲以及低收入和中等收入国家中接受血液透析患者的流行病学数据有限。
利用危地马拉第二大透析网络的电子病历,我们对所有确诊为COVID-19的成年血液透析患者进行了回顾性分析,以估计感染发生率,并描述人口统计学特征、合并症和治疗结果。我们按地区对发病率进行了分层。我们回顾了2020年5月1日至7月31日的数据,截至2020年8月28日确定了治疗结果数据。
在3201例接受血液透析的患者中,325例被诊断为COVID-19(血液透析患者的发病率为102/1000,而普通人群为3/1000)。中部地区的发病率较高(207/1000),东南部地区最低(33/1000),与普通人群不同,危地马拉城的发病率较低。确诊为COVID-19的患者平均年龄为51.1岁(标准差[SD]14.8岁),84例(25.8%)为女性。住院时间中位数为12天(四分位间距[IQR]10 - 16天)。229例(69.8%)患者康复,90例死亡(27.7%),6例(1.8%)患者在最后一次随访时仍住院。
危地马拉接受血液透析患者中确诊的COVID-19发病率远高于普通人群报告的发病率,其治疗结果与高收入国家描述的相似。农村地区的发病率高于主要大都市地区。